Pfizer Making Strides To Fill Future Lipitor Gap
This article was originally published in The Pink Sheet Daily
Pfizer demonstrates its "balanced portfolio" approach, with five recent deals, but concerns linger about its ability to meet its 2012 financial targets .
You may also be interested in...
Biogen’s purchase of Stromedix completes the buy-up of independently held biotech assets in the furious competition to take the lead in idiopathic pulmonary fibrosis.
SINGAPORE - Pfizer Australia will begin direct sales of its prescription medicines to pharmacies in early 2011, cutting out distributors as part of a global battle to go head-to-head against generic copies of blockbuster drugs like Lipitor that face patent expiry in the coming years